A team of Gleiss Lutz lawyers provided the start-up DiosCURE Therapeutics with extensive and cross-disciplinary advice on the formation, the set-up of corporate structures as well as in connection with the seed financing. DiosCURE Therapeutics develops active ingredients for the prevention and treatment of COVID-19 illnesses. The first positive research results relating to the relevant drug candidates were recently published in the specialist journal 'Science'.
Gleiss Lutz advised DiosCURE Therapeutics extensively during the formation phase, on the seed financing and on all the relevant subsequent steps. In the seed financing round, DiosCURE Therapeutics raised investments of EUR 2.6 million from well-known venture capital firms and angel investors.
DiosCURE Therapeutics develops immunotherapies that focus on a novel approach against SARS-CoV-2. The lead active ingredient candidates, DIOS-202 and DIOS-203, developed by DiosCURE target different epitopes of the SARS-CoV-2 spike protein and have the potential to provide a highly efficacious and well-tolerated COVID-19 therapy that can be manufactured on a large scale in a standardised process. The ground-breaking research of DiosCURE Therapeutics is based on a cooperation between the Institute of Innate Immunity at the University of Bonn, the Scripps Research Institute in San Diego and the Karolinska Institutet in Stockholm.
DiosCURE was advised by the following team of Gleiss Lutz lawyers: Dr. Martin Viciano Gofferje (partner, lead), Dr. Micha Christopher Pfarr, Vanessa Sánchez López, Dr. Christoph Meissner, Dr. Viktor Gorlow (all Corporate/M&A), Dr. Alexander Molle (partner), Dr. Matthias Schilde, Felix Müller (all IP/IT), Dr. Enno Burk (counsel, Regulatory, all Berlin).
Forward
